Asian Spectator


The Times

.

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

  • Written by PR Newswire Asia - Asian Spectator

SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with...

Magazine

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

Why Early Protection of Intellectual Assets is Critical

For many businesses, intellectual assets are among the most valuable things they own, yet they're often the last to receive formal legal protection. A brand name or a proprietary process can represe...

Konservasi gaya lama tak efektif: Pemulihan Aceh perlu warga dengan ekonomi yang merawat hutan

shutterstock(Manthofana/Shutterstock)● Peminggiran warga dari konservasi hutan Lingga Isaq menjadi salah satu faktor yang memperparah dampak bencana.● Pertanian monokultur dan tambang emas...

hacklink hack forum hacklink film izle hacklink z-libraryGrandpashabetgrandpashabetDeneme bonusu veren siteler 2026Deneme bonusu veren siteler 2026Grandpashabetmarsbahis giriş爱思助手下载aresbettelegram下载jojobet girişgrandpashabetgrandpashabet twiter xbetparktelegram webroyalbet girişcasibomjojobetdeneme bonususlot sitelerideneme bonusujojobetjojobetjojobetjojobetcasibom